{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:39:28Z","timestamp":1792823968041,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2023ZD0501200"],"award-info":[{"award-number":["2023ZD0501200"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012492","name":"Beijing Municipal Outstanding Young Talents","doi-asserted-by":"publisher","award":["JWZQ20240101001"],"award-info":[{"award-number":["JWZQ20240101001"]}],"id":[{"id":"10.13039\/100012492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.canlet.2026.218865","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:31:14Z","timestamp":1790922674000},"page":"218865","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Rapid manufactured CAR-T cells enriched for CD45RA-negative T cells exhibit superior persistence compared to conventional CAR-T therapy"],"prefix":"10.1016","volume":"661","author":[{"given":"Xuying","family":"Pei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuojun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luhan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhipeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8139-1773","authenticated-orcid":false,"given":"Xiangyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10299","key":"10.1016\/j.canlet.2026.218865_bib1","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.canlet.2026.218865_bib2","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","article-title":"Obecabtagene autoleucel in adults with B-Cell acute lymphoblastic leukemia","volume":"391","author":"Roddie","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218865_bib3","article-title":"Outcomes after Brexucabtagene autoleucel administered as a standard therapy for adults with Relapsed\/Refractory B-Cell ALL","author":"Roloff","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218865_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2024.101241","article-title":"Advancing CAR T-cell therapies: preclinical insights and clinical translation for hematological malignancies","volume":"68","author":"Arunachalam","year":"2024","journal-title":"Blood Rev."},{"issue":"12","key":"10.1016\/j.canlet.2026.218865_bib5","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/OP.22.00315","article-title":"Chimeric antigen receptor T-Cell therapies: barriers and solutions to access","volume":"18","author":"Mikhael","year":"2022","journal-title":"JCO Oncol. Pract."},{"issue":"10","key":"10.1016\/j.canlet.2026.218865_bib6","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/ajh.26301","article-title":"Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed\/refractory aggressive B-cell lymphomas: observations from the JULIET, ZUMA-1, and TRANSCEND trials","volume":"96","author":"Westin","year":"2021","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218865_bib7","article-title":"Tumor-infiltrating CD45RO+ memory T lymphocytes predict favorable clinical outcome in solid tumors","volume":"7","author":"Hu","year":"2017","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.canlet.2026.218865_bib8","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41551-021-00842-6","article-title":"Rapid manufacturing of non-activated potent CAR T cells","volume":"6","author":"Ghassemi","year":"2022","journal-title":"Nat. Biomed. Eng."},{"issue":"8","key":"10.1016\/j.canlet.2026.218865_bib9","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.3324\/haematol.2022.282316","article-title":"Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: chinese experience","volume":"108","author":"Sun","year":"2023","journal-title":"Haematologica"},{"issue":"19","key":"10.1016\/j.canlet.2026.218865_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910828","article-title":"Improving CAR T-Cell persistence","volume":"22","author":"Pietrobon","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.canlet.2026.218865_bib11","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/imcb.12254","article-title":"Chimeric antigen receptor T cell persistence and memory cell formation","volume":"97","author":"McLellan","year":"2019","journal-title":"Immunol. Cell Biol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218865_bib12","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s44178-024-00117-5","article-title":"CAR-T cell therapy shines as a beam of hope in the fight against acute leukemia","volume":"3","author":"Sun","year":"2024","journal-title":"Holistic Integrative Oncol."},{"issue":"9","key":"10.1016\/j.canlet.2026.218865_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009476","article-title":"BCMA-BBZ-OX40 CAR-T therapy using an instant manufacturing platform in multiple myeloma","volume":"12","author":"Wang","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.canlet.2026.218865_bib14","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41408-022-00688-4","article-title":"Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia","volume":"12","author":"Zhang","year":"2022","journal-title":"Blood Cancer J."},{"issue":"9","key":"10.1016\/j.canlet.2026.218865_bib15","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1158\/2159-8290.CD-22-1276","article-title":"A novel autologous CAR-T therapy, YTB323, with preserved T-cell stemness shows enhanced CAR T-cell efficacy in preclinical and early clinical development","volume":"13","author":"Dickinson","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218865_bib16","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.omto.2023.04.003","article-title":"Durable remission related to CAR-T persistence in R\/R B-ALL and long-term persistence potential of prime CAR-T","volume":"29","author":"Shiqi","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"issue":"12","key":"10.1016\/j.canlet.2026.218865_bib17","article-title":"Rapidly manufactured CAR-T with conserved cell stemness and distinctive cytokine-secreting profile shows improved anti-tumor efficacy","volume":"12","author":"Tsao","year":"2024","journal-title":"Vaccines (Basel)"},{"issue":"7","key":"10.1016\/j.canlet.2026.218865_bib18","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41408-022-00694-6","article-title":"Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study","volume":"12","author":"Yang","year":"2022","journal-title":"Blood Cancer J."},{"issue":"19","key":"10.1016\/j.canlet.2026.218865_bib19","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/blood.2023020794","article-title":"Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel","volume":"143","author":"G\u00f6kbuget","year":"2024","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.canlet.2026.218865_bib20","doi-asserted-by":"crossref","first-page":"563","DOI":"10.6004\/jnccn.2024.0051","article-title":"Acute lymphoblastic leukemia, version 2.2024, NCCN Clinical Practice Guidelines in oncology","volume":"22","author":"Shah","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"3","key":"10.1016\/j.canlet.2026.218865_bib21","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.canlet.2026.218865_bib22","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.canlet.2026.218865_bib23","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1910844119","article-title":"CD81 costimulation skews CAR transduction toward naive T cells","volume":"119","author":"Schultz","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA."},{"issue":"18","key":"10.1016\/j.canlet.2026.218865_bib24","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1128\/MCB.00302-13","article-title":"CD81 controls sustained T cell activation signaling and defines the maturation stages of cognate immunological synapses","volume":"33","author":"Rocha-Perugini","year":"2013","journal-title":"Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218865_bib25","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41467-017-00573-w","article-title":"Signalling strength determines proapoptotic functions of STING","volume":"8","author":"Gulen","year":"2017","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.canlet.2026.218865_bib26","doi-asserted-by":"crossref","first-page":"9464","DOI":"10.1038\/s41467-024-53706-3","article-title":"Prostaglandin E2-EP2\/EP4 signaling induces immunosuppression in human cancer by impairing bioenergetics and ribosome biogenesis in immune cells","volume":"15","author":"Punyawatthananukool","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.canlet.2026.218865_bib27","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41467-024-45340-w","article-title":"UPP1 promotes lung adenocarcinoma progression through the induction of an immunosuppressive microenvironment","volume":"15","author":"Li","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218865_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107742","article-title":"CD4(+)CD25(+)CD127(low) regulatory T cells associated with the effect of CD19 CAR-T therapy for relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"96","author":"Pan","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.canlet.2026.218865_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcyt.2025.04.068","article-title":"A new sort of cells for chimeric antigen receptor T-cell therapies-isolating CD14(-)CD127(+) T cells for chimeric antigen receptor T-cell manufacture","author":"Luo","year":"2025","journal-title":"Cytotherapy"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526006294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526006294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:19:57Z","timestamp":1792822797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526006294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":29,"alternative-id":["S0304383526006294"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218865","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rapid manufactured CAR-T cells enriched for CD45RA-negative T cells exhibit superior persistence compared to conventional CAR-T therapy","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218865","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218865"}}